Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point of care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

For more information, click below.


Subscribers log in here


Treatment of male sexual dysfunction

INTRODUCTION

The three major forms of male sexual dysfunction are erectile dysfunction, ejaculatory dysfunction, and decreased libido. Erectile dysfunction is a common problem in men over the age of 40 due to hormonal abnormalities, medications, psychological problems, neurologic disease, or vascular insufficiency. Men with this disorder experience significant psychological distress, which improves if treatment successfully restores erectile function [1]. Premature ejaculation may be another troublesome form of sexual dysfunction [2].

The treatment of male sexual dysfunction is reviewed here. Erectile physiology and the major causes of erectile dysfunction are discussed in detail elsewhere. (See "Overview of male sexual dysfunction" and "Evaluation of male sexual dysfunction".)

Guidelines from the American Urological Association (AUA) have been published for the treatment of erectile dysfunction [3] and premature ejaculation [2]. The American College of Physicians [4] and The American Association of Clinical Endocrinologists have also issued treatment guidelines [5].

GENERAL PRINCIPLES

The first step in the treatment of male sexual dysfunction is to determine the etiology. Certain clues in the history and appropriate laboratory testing can usually establish the primary cause (table 1). (See "Evaluation of male sexual dysfunction".)

Erectile dysfunction and cardiovascular disease share many risk factors, and their pathophysiology is mediated through endothelial dysfunction. Cardiovascular disease and its risk factors increase the risk for later erectile dysfunction (ED); on the other hand, erectile dysfunction may be an early warning sign of future cardiovascular events (see "Overview of male sexual dysfunction", section on 'Association with cardiovascular disease'). Lifestyle modifications such as diet and exercise, in addition to reducing cardiovascular risk factors, may improve ED as well. Cardiovascular risk factor reduction with pharmacotherapy may also improve ED.

                                          

Subscribers log in here

To continue reading this article you must have access through your hospital or your group practice, log in to your personal subscription, or purchase a personal subscription. For more information, click below.
Literature review current through: Apr 2013. | This topic last updated: May 1, 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2013 UpToDate, Inc.
References
Top
  1. Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study. BMJ 2004; 328:1037.
  2. Montague DK, Jarow J, Broderick GA, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004; 172:290.
  3. Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005; 174:230.
  4. Qaseem A, Snow V, Denberg TD, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2009; 151:639.
  5. Guay AT, Spark RF, Bansal S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update. Endocr Pract 2003; 9:77.
  6. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291:2978.
  7. Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 2006; 18:405.
  8. Wing RR, Rosen RC, Fava JL, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med 2010; 7:156.
  9. Lamina S, Okoye CG, Dagogo TT. Therapeutic effect of an interval exercise training program in the management of erectile dysfunction in hypertensive patients. J Clin Hypertens (Greenwich) 2009; 11:125.
  10. Gupta BP, Murad MH, Clifton MM, et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2011; 171:1797.
  11. Dadkhah F, Safarinejad MR, Asgari MA, et al. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res 2010; 22:51.
  12. Herrmann HC, Levine LA, Macaluso J Jr, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 2006; 3:303.
  13. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78:257.
  14. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338:1397.
  15. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999; 281:421.
  16. Schover LR, Fouladi RT, Warneke CL, et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002; 95:2397.
  17. Zippe CD, Kedia AW, Kedia K, et al. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 1998; 52:963.
  18. Dinsmore WW, Hodges M, Hargreaves C, et al. Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999; 53:800.
  19. Fink HA, Mac Donald R, Rutks IR, et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002; 162:1349.
  20. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172:658.
  21. Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000; 86:57F.
  22. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36:25.
  23. Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287:719.
  24. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342:1622.
  25. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999; 99:168.
  26. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96:313.
  27. Stauffer JC, Ruiz V, Morard JD. Subaortic obstruction after sildenafil in a patient with hypertrophic cardiomyopathy. N Engl J Med 1999; 341:700.
  28. Pomara G, Morelli G, Pomara S, et al. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. J Androl 2004; 25:625.
  29. The Medical Letter December 22. 2003; 45:101.
  30. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172:1935.
  31. Vobig MA, Klotz T, Staak M, et al. Retinal side-effects of sildenafil. Lancet 1999; 353:375.
  32. The Medical Letter 2005; 47:49.
  33. http://www.fda.gov/cder/consumerinfo/viagra/vIAGRA.htm (accessed online 7/11/05).
  34. Zrenner E. No cause for alarm over retinal side-effects of sildenafil. Lancet 1999; 353:340.
  35. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01730.html (accessed on 10/22/07).
  36. Aversa A, Mazzilli F, Rossi T, et al. Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Hum Reprod 2000; 15:131.
  37. Kim KK, Kim DG, Ku YH, et al. Bilateral cerebral hemispheric infarction associated with sildenafil citrate (Viagra) use. Eur J Neurol 2008; 15:306.
  38. Alpsan MH, Bebek N, Ciftci FD, et al. Intracerebral hemorrhage associated with sildenafil use: a case report. J Neurol 2008; 255:932.
  39. Swearingen SG, Klausner JD. Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection. Am J Med 2005; 118:571.
  40. Vardenafil (levitra) for erectile dysfunction. Med Lett Drugs Ther 2003; 45:77.
  41. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13:192.
  42. Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19:32.
  43. Hellstrom WJ, Gittelman M, Karlin G, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61:8.
  44. Valiquette L, Young JM, Moncada I, et al. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2005; 80:1291.
  45. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26:777.
  46. Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170:1278.
  47. Rajagopalan P, Mazzu A, Xia C, et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003; 43:260.
  48. Borer J, Armstrong P, Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. Circulation 2003; 107:e9052.
  49. www.fda.gov/cder/warn/2005/Levitra.pdf.
  50. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56:453.
  51. Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003; 62:121.
  52. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14 Suppl 1:S57.
  53. "The Pink Sheet". 2003; 65:23.
  54. Tadalafil (Cialis) once a day for erectile dysfunction. Med Lett Drugs Ther 2008; 50:27.
  55. Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50:351.
  56. Bella AJ, Brock GB. Tadalafil in the treatment of erectile dysfunction. Curr Urol Rep 2003; 4:472.
  57. http://www.fda.gov/CDER/DRUG/infopage/cialis/cialisQ&A.htm (accessed on 5/29/08).
  58. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168:1332.
  59. Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42:1855.
  60. Pharmaceutical Approvals Monthly April 2004; 9:21.
  61. Cordell WH, Maturi RK, Costigan TM, et al. Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol 2009; 127:367.
  62. Hellstrom WJ, Overstreet JW, Yu A, et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003; 170:887.
  63. McCullough AR, Steidle CP, Klee B, Tseng LJ. Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose. Urology 2008; 71:686.
  64. Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25:2709.
  65. Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009; 151:650.
  66. www.fda.gov/bbs/topics/ANSWERS/2003/ANS01235.html (Accessed 3/7/05).
  67. Mitka M. FDA issues warning on "all-natural" herbal product found to contain viagra. JAMA 2003; 289:2786.
  68. Venhuis BJ, Blok-Tip L, de Kaste D. Designer drugs in herbal aphrodisiacs. Forensic Sci Int 2008; 177:e25.
  69. Savaliya AA, Shah RP, Prasad B, Singh S. Screening of Indian aphrodisiac ayurvedic/herbal healthcare products for adulteration with sildenafil, tadalafil and/or vardenafil using LC/PDA and extracted ion LC-MS/TOF. J Pharm Biomed Anal 2010; 52:406.
  70. Hatzimouratidis K, Moysidis K, Bekos A, et al. Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study. Eur Urol 2006; 50:126.
  71. Gruenwald I, Shenfeld O, Chen J, et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006; 50:134.
  72. Govier FE, McClure RD, Weissman RM, et al. Experience with triple-drug therapy in a pharmacological erection program. J Urol 1993; 150:1822.
  73. Shenfeld O, Hanani J, Shalhav A, et al. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J Urol 1995; 154:1017.
  74. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996; 334:873.
  75. Carson, CC 3rd, Mino, RD. Priapism associated with trazodone therapy. J Urol 1988; 139:369.
  76. Kulmala RV, Tamella TL. Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs. Int J Impot Res 1995; 7:131.
  77. Levine SB, Althof SE, Turner LA, et al. Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141:54.
  78. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997; 336:1.
  79. Tay KP, Lim PH. A prospective trial with vacuum-assisted erection devices. Ann Acad Med Singapore 1995; 24:705.
  80. Herman JB, Brotman AW, Pollack MH, et al. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990; 51:25.
  81. Riley, AJ, Goodman, RE, Kellett, JM, et al. Double blind trial of yohimbine hydrochloride in erection inadequacy. J Sexual Marital Therapy 1989; 4:17.
  82. Montorsi F, Strambi LF, Guazzoni G, et al. Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology 1994; 44:732.
  83. Kunelius P, Häkkinen J, Lukkarinen O. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urology 1997; 49:441.
  84. Knoll LD, Benson RC Jr, Bilhartz DL, et al. A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence. J Urol 1996; 155:144.
  85. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159:433.
  86. Wespes E, Wildschutz T, Roumeguere T, Schulman CC. The place of surgery for vascular impotence in the third millennium. J Urol 2003; 170:1284.
  87. Siroky MB, Azadzoi KM. Vasculogenic erectile dysfunction: newer therapeutic strategies. J Urol 2003; 170:S24.
  88. Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004; 16:51.
  89. Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology 2005; 65:755.
  90. Gregoire A. ABC of sexual health: assessing and managing male sexual problems. BMJ 1999; 318:315.
  91. McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 1998; 159:1935.
  92. Kara H, Aydin S, Yücel M, et al. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol 1996; 156:1631.
  93. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 1994; 151:1377.
  94. McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol 1999; 161:1826.
  95. Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006; 368:929.
  96. Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 1998; 159:425.
  97. Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001; 13:41.